Thyroid Cancer 1.4 X higher risk if low vitamin D– meta-analysis Feb 2018

---

Thyroid Cancer outcomes greatly improved with Vitamin D supplementation – Aug 2023

Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study
Cancer Immunol Immunother . 2023 Aug 28. doi: 10.1007/s00262-023-03522-3
Melissa Bersanelli # 1 2, Alessio Cortellini # 3 4, Alessandro Leonetti 1 2, Alessandro Parisi 5, Marcello Tiseo 1 2 6, Paola Bordi 1, Maria Michiara 1, Simona Bui 1, Agnese Cosenza 1, Leonarda Ferri 1, Giulia Claire Giudice 1 6, Irene Testi 1 6, Elena Rapacchi 1, Roberta Camisa 1, Bruno Vincenzi 7, Giuseppe Caruso 1, Antonio Natale Rauti 6, Federica Arturi 6, Marco Tucci 8, Valentina Santo 7, Valentina Ricozzi 7, Vanessa Burtet 9, Paolo Sgargi 10, Renata Todeschini 2, Fable Zustovich 11, Luigia Stefania Stucci 12, Daniele Santini 13, Sebastiano Buti 1 2 6

Background: Hypovitaminosis D can have a negative prognostic impact in patients with cancer. Vitamin D has a demonstrated role in T-cell-mediated immune activation. We hypothesized that systematic vitamin D repletion could impact clinical outcomes in patients with cancer receiving immune-checkpoint inhibitors (ICIs).

Methods: We planned a prospective observational study (PROVIDENCE) to assess serum vitamin D levels in patients with advanced cancer receiving ICIs (cohort 1 at treatment initiation, cohort 2 during treatment) and the impact of systematic repletion on survival and toxicity outcomes. In an exploratory analysis, we compared the clinical outcomes of cohort 1 with a control cohort of patients followed at the participating centers who did not receive systematic vitamin D repletion.

Results: Overall, 164 patients were prospectively recruited in the PROVIDENCE study. In cohort 1, consisting of 101 patients with 94.1% hypovitaminosis (≤ 30 ng/ml) at baseline, adequate repletion with cholecalciferol was obtained in 70.1% at the three months re-assessment. Cohort 2 consisted of 63 patients assessed for vitamin D at a median time of 3.7 months since immunotherapy initiation, with no patients having adequate levels (> 30 ng/ml). Even in cohort 2, systematic supplementation led to adequate levels in 77.8% of patients at the three months re-assessment. Compared to a retrospective control group of 238 patients without systematic vitamin D repletion, PROVIDENCE cohort 1 showed longer overall survival (OS, p = 0.013), time to treatment failure (TTF, p = 0.017), and higher disease control rate (DCR, p = 0.016). The Inverse Probability of Treatment Weighing (IPTW) fitted multivariable Cox regression confirmed the significantly decreased risk of death (HR 0.55, 95%CI: 0.34-0.90) and treatment discontinuation (HR 0.61, 95%CI: 0.40-0.91) for patients from PROVIDENCE cohort 1 in comparison to the control cohort. In the context of longer treatment exposure, the cumulative incidence of any grade immune-related adverse events (irAEs) was higher in the PROVIDENCE cohort 1 compared to the control cohort. Nevertheless, patients from cohort 1 experienced a significantly decreased risk of all grade thyroid irAEs than the control cohort (OR 0.16, 95%CI: 0.03-0.85).

Conclusion: The PROVIDENCE study suggests the potential positive impact of early systematic vitamin D supplementation on outcomes of patients with advanced cancer receiving ICIs and support adequate repletion as a possible prophylaxis for thyroid irAEs.

 Download the PDF from VitaminDWiki

Italian Guidelines for Vitamin D supplementation in hospital (clipped from PDF)

At enrollment, vitamin D supplementation was system­atically offered to patients starting within 28 days from the assessment, following the guidelines of the Italian Society of Osteoporosis, Mineral Metabolism, and Bone Disease (SIOMMMS [18]) as follows:

• Adequate level group: no supplementation.
• Insufficiency group: cholecalciferol (vitamin D3) at the loading dose of 300,000 International Units (IU) over 4 weeks, maintenance dose of 820 IU daily.
• Deficiency group: cholecalciferol at the loading dose of 600,000 International Units (IU) over 4 weeks, mainte­nance dose of 1000 IU daily.
• Severe deficiency group: cholecalciferol at the load­ing dose of 1,000,000 International Units (IU) over 4 weeks, maintenance dose of 2000 IU daily.
  • Comment by VitaminDWiki: loading dose seems correct, maintenance doses are too small

---

Association between vitamin D deficiency and risk of thyroid cancer: a case-control study and a meta-analysis - Feb 2018

J Endocrinol Invest. 2018 Feb 20. doi:10.1007/s40618-018-0853-9
Hu MJ1, Zhang Q1, Liang L1, Wang SY2, Zheng XC2, Zhou MM1, Yang YW1, Zhong Q1, Huang F3.

PURPOSE: Although vitamin D is reportedly associated with various cancers, the association between vitamin D and thyroid cancer is indefinite. We aimed to investigate whether this association applies to thyroid cancer (TC).

METHODS:
A total of 276 Chinese Han people were recruited in a current matched case-control study. Multivariable conditional logistic regression was computed to estimate the association between plasma 25(OH)D and papillary thyroid cancer (PTC). In addition, we searched relevant studies in PubMed and Web of Science databases before December 2017 to conduct a meta-analysis.

RESULTS:
In our case-control study, plasma 25(OH)D concentration was inversely associated with PTC risk (highest tertile vs lowest tertile: adjusted OR = 0.25; 95% CI 0.10, 0.61; Ptrend = 0.003). This association was independent of body mass index and physical activity (all adjusted Pinteraction > 0.05).
A total of 11 studies were included in the meta-analysis, among which ten studies have been published and one was our case-control study. Compared with 25(OH)D non-deficient group, the pooled OR of TC was 1.42 (95% CI 1.17, 1.73) in the deficient group. Similarly, blood 25(OH)D levels in patients with TC were tend to be lower than those in the controls (SMD = - 0.20, 95% CI - 0.36, - 0.03).

CONCLUSIONS: A high level of circulating 25(OH)D was associated with a decreased TC risk. This association has important significance in public health and should, therefore, be further studied.

---

Vitamin D-Related Genes and Thyroid Cancer—A Systematic Review - Nov 2022 (no associations found)

Int. J. Mol. Sci. 2022, 23(21), 13661; https://doi.org/10.3390/ijms232113661
by Adam Maciejewski and Katarzyna Lacka
Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, 60355 Poznan, Poland

Vitamin D, formerly known for its role in calcium-phosphorus homeostasis, was shown to exert a broad influence on immunity and on differentiation and proliferation processes in the last few years. In the field of endocrinology, there is proof of the potential role of vitamin D and vitamin D-related genes in the pathogenesis of thyroid cancer—the most prevalent endocrine malignancy. Therefore, the study aimed to systematically review the publications on the association between vitamin D-related gene variants (polymorphisms, mutations, etc.) and thyroid cancer. PubMed, EMBASE, Scopus, and Web of Science electronic databases were searched for relevant studies. A total of ten studies were found that met the inclusion criteria.
Six vitamin D-related genes were analyzed (

• VDR—vitamin D receptor,
• CYP2R1—cytochrome P450 family 2 subfamily R member 1,
• CYP24A1—cytochrome P450 family 24 subfamily A member 1,
• CYP27B1—cytochrome P450 family 27 subfamily B member 1,
• DHCR7—7-dehydrocholesterol reductase and
• CUBN—cubilin).

Moreover, a meta-analysis was conducted to summarize the data from the studies on VDR polymorphisms (rs2228570/FokI, rs1544410/BsmI, rs7975232/ApaI and rs731236/TaqI). Some associations between thyroid cancer risk (VDR, CYP24A1, DHCR7) or the clinical course of the disease (VDR) and vitamin D-related gene polymorphisms were described in the literature. However, these results seem inconclusive and need validation. A meta-analysis of the five studies of common VDR polymorphisms did not confirm their association with increased susceptibility to differentiated thyroid cancer. Further efforts are necessary to improve our understanding of thyroid cancer pathogenesis and implement targeted therapies for refractory cases
 Download the PDF from VitaminDWiki

---

VitaminDWiki: Cancer- Other category with THYROID in title (7 as of Oct 2022)

This list is automatically updated

---

VitaminDWiki - Cancer category (includes a VDR section)

• Cancer 266 items Overview Cancer and vitamin D
• Cancer and Vitamin D - many studies
• After Cancer Diagnosis 103 items
• Bladder Cancer 26 items
• Breast Cancer 248 items Overview Breast Cancer and Vitamin D
• Colon Cancer 138 items Overview Cancer-Colon and vitamin D
• Leukemia 19 items
• Liver Cancer 17 items
• Lung Cancer 54 items Overview Lung cancer and vitamin D
• Lymphoma Cancer 23 items
• Other Cancer 62 items
• Ovarian Cancer 24 items
• Pancreatic Cancer 55 items
• Prostate Cancer 97 items Overview Prostate Cancer and Vitamin D
• Skin Cancer 119 items Overview Suntan, melanoma and vitamin D
• Easiest way to treat cancer – take Vitamin D – Nov 2022
• 2X increase of 14 cancers in non-seniors in 20 years (low vitamin D) – Sept 2022
• Vitamin D prevents and treats cancer in many ways – May 2021
• Those with recent cancer diagnosis had 7X increased risk of COVID-19 (more if A-A )- Dec 2020
• Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
• Cancer incidence and mortality is decreased if 40-60 ng of Vitamin D – April 2019
• 8 ways that Cancer might be prevented by Vitamin D - June 2019
• Cancer stem cells and Vitamin D - many studies
• Vitamin D Reduces Cancer Risk - Why Scientists Accept It but Physicians Do Not - Feb 2019
• Overview of Vitamin D Actions in Cancer – 31 page chapter in a book – 2018
• Vitamin D prevents breast cancer, reduces BC mortality, and reduces BC chemotherapy problems – Sept 2018
• Diagnosed with breast cancer – take vitamin D to cut chance of death by half – July 2018
• Melanoma 25 X more likely if low vitamin D – Feb 2018
• Better Cancer survival if higher vitamin D a decade earlier (esp. Melanoma, Kidney, Prostate)– Aug 2018

Cancers get less Vitamin D when there is a poor Vitamin D Receptor

• Vitamin D Receptor pages in VitaminDWiki with CANCER in title 86 as of July 2023
• Cancer and the Vitamin D Receptor, a primer – Sept 2017
• Vitamin D Receptor and Cancer
• Risk of Cancer increased if poor Vitamin D Receptor – meta-analysis of 73 studies Jan 2016
• Cancer (general) and VDR 23 articles
• Breast Cancer and VDR 20 articles
• Colon Cancer and VDR 13 articles
• Prostate Cancer and VDR 7 articles
• Skin Cancer and VDR 10 articles
  • Note some Health problems, such as some Cancers, protect themselves
    by actively reducing Receptor activation